

Can the skin forget psoriasis?



Treat early* with TREMFYA® to target disease memory and achieve a deep, durable response^{†‡1-3}

“Although my skin is now clear, I am still scared that my psoriasis will come back”

Discover Hanna's story



Visit us at booth **A23** to find out more!

Start Strong, **Go Long**^{\$1,4,5}

*In patients who had their first Pso symptoms ≤2 years before screening.⁶

†TRM cells remain in the skin even after lesions have healed, creating a disease memory;⁷ TREMFYA® has demonstrated reduction of TRM cells to levels similar to non-lesional skin.³

‡A “deep” response comprises TRM cell reduction and complete skin clearance.^{1,3}

\$Strong: ECLIPSE: PASI 90 = 84% at Week 48 (n=534).⁴ VOYAGE-1: PASI 90 & IGA 0/1 = 73.3% and 85.1% at Week 16 (n=329), respectively; PASI 100 = 44.4% at Week 24 (n=329).⁵ Long: VOYAGE-1: PASI 90 = 84.1% at Week 252 (n=391, TREMFYA® open-label at Week 52, includes patients randomised to TREMFYA® at baseline and those randomised to placebo at baseline who crossed over to receive TREMFYA® at Week 16, TFR).¹

IGA, Investigator's Global Assessment; PASI, Psoriasis Area and Severity Index; TFR, treatment failure rules; TRM, tissue-resident memory T cells.

REFERENCES: **1.** Reich K, et al. *Br J Dermatol.* 2021;185:1146–1159. **2.** Mehta H, et al. *J Invest Dermatol.* 2021;141:1707–1718. **3.** Eyerich K, et al. *JAMA Dermatol.* 2024:e242463. **4.** Blauvelt A, et al. *J Am Acad Dermatol.* 2017;76:405–417. **5.** Reich K, et al. *Br J Dermatol.* 2021;185:1146–1159. **6.** Eyerich K, et al. *BMJ Open.* 2021;11(9):e049822. **7.** Cheuk S, et al. *J Immunol.* 2014;192(7):3111–3120.

The Product Information for countries outside the EU may differ. Please consult your local health authorities for information about your local Product Information. SmPC available at the booth.

Janssen Pharmaceutica N.V., a company of Johnson & Johnson in EMEA, Janssen Pharmaceutica NV, Turnhoutseweg 30, B-2340 Beerse, Belgium

CP-464935 | August 2024